Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-02-05 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
2023 年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and votes. There is no financial data or report content, only the official voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2250 characters), consistent with a voting results announcement rather than a full report or presentation.
2023-02-05 Chinese
2023年第一次临时股东大会法律意见书
Regulatory Filings
2023-02-05 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the repurchase scheme, including the number of shares repurchased, prices, funds used, and progress as of a specific date. It does not contain financial statements or comprehensive financial data but rather updates on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2023-01-31 Chinese
关于公司被认定为 2022 年度广东省专精特新中小企业的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (705 characters) regarding the company's recognition as a specialized and innovative small and medium enterprise by a provincial government department. It does not contain financial data, audit information, management changes, or any report content. It is a regulatory announcement about a status recognition, not a financial or governance report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-01-19 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangdong Yongshun Biological Pharmaceutical Co., Ltd. regarding the acquisition of a new veterinary drug registration certificate. It details the approval by the Ministry of Agriculture and Rural Affairs of China for a new veterinary drug product, including its registration number, classification, and product information. The document also discusses the product's development background, market context, and the necessary procedures before the product can be marketed. It includes a risk warning about the pending approval for product sales. The document is short (1236 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-01-16 Chinese
关于预计 2023 年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the year 2023 by Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes detailed projections of transaction amounts with related parties, descriptions of the nature of these transactions, the basic information of related parties, and the approval and review process by the board and supervisory committee. The document also contains opinions from independent directors and the sponsor institution, confirming the fairness and compliance of the transactions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or interim report. The document is a regulatory announcement about expected related party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure and does not constitute a financial report or other specific filing type.
2023-01-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.